ArgusEye – one of Sweden’s top Startups 2022
ArgusEye has been listed in the prestigious 33-listan by [...]
ArgusEye closes deal with the downstream group within biological development at Bayer AG
The multinational pharmaceutical and biotechnology company, Bayer AG, has [...]
Another successful week for ArgusEye during TESTA Challenge 2022
During March 14 – April 1, ArgusEye participated in [...]
ArgusEye selected for TESTA Challenge 2022
ArgusEye has again been selected to participate in TESTA Challenge [...]
ArgusEye completes oversubscribed seed funding round
ArgusEye has successfully completed its first external financing round, securing [...]
A successful week for ArgusEye during TESTA Challenge 2020
During October 19-23, ArgusEye participated in TESTA Challenge in Uppsala. [...]
ArgusEye selected for TESTA Challenge 2020
ArgusEye has been selected to participate in TESTA Challenge 2020 [...]
ArgusEye at NLS Days 2019, September 10-12
ArgusEye’s CEO Dr. Erik Martinsson will participate at the Nordic [...]
ArgusEye receives new grant from Vinnova
In tough competition with other innovative start-up companies, ArgusEye [...]
ArgusEye is granted 500 000 SEK from Vinnova
ArgusEye AB is granted 500 000 SEK from Vinnova’s Runner [...]